Financial agenda for 2025

Villepinte, 31 October 2024: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025.

About Guerbet

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years, with more than 2,600 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, in United States and Isra?l. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €786 million in revenue in 2023.

Contacts:

Guerbet     
Jér?me Estampes, Chief Financial Officer + 33 1 45 91 50 00 / [email protected] 
Christine Allard, Head of Public Affairs and Communications: +33 6 30 11 57 82 / [email protected]

Seitosei.Actifin                                                                                       
Marianne Py, Financial Communication + 33 1 80 48 25 31 / [email protected]
Jennifer Jullia, Press +33 1 56 88 11 19 / [email protected]

Attachment

• GUERBET_Agenda financier 2025 EN